Großzellig-anaplastisches T-Zell-Lymphom und Mycosis fungoides unter der Therapie mit Dupilumab

Zusammenfassung

Dupilumab ist das erste zielgerichtete Biologikum, das bei mittelschwerer bis schwerer atopischer Dermatitis angewendet werden kann. Der monoklonale Antikörper hemmt die Interleukin-4- und Interleukin-13-Signalübertragung [1]. Dupilumab belegt für die Behandlung von atopischen und allergischen Erkrankungen ein gutes Verträglichkeitsprofil. Gleichwohl sollten Ärzte seine Neuheit und das Potenzial für unerwartete und unerwünschte Arzneimittelwirkungen berücksichtigen. Wir stellen einen Patienten vor, der nach Einleitung von Dupilumab ein großzellig-anaplastisches T-Zell-Lymphom mit Befall des supraklavikulären Lymphknotens und eine Mycosis fungoides entwickelte.

Abstract

Dupilumab is the first targeted biologic therapy that can be used in moderate to severe atopic dermatitis. The monoclonal antibody inhibits interleukin-4 and interleukin-13 signal transmission [1]. Dupilumab has a good tolerance profile for the treatment of atopic and allergic diseases. Clinicians should consider its novelty and the potential for unexpected and adverse drug reactions. We present a patient who developed a large-cell anaplastic T-cell lymphoma with involvement of the supraclavicular lymph node and mycosis fungoides after induction of dupilumab.

• Literatur

• 1 Gooderham MJ, Hong HC-h, Eshtiaghi P. et al. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol 2018; 78: S28-S36 [PMID: 29471919]
• 2 Campo E, Swerdlow SH, Harris NL. et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-5032
• 3 Stein H, Foss HD, Dürkop H. et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000; 96: 3681-3695
• 4 Hodak E, Amitay-Laish I. Mycosis fungoides: A great imitator. Clin Dermatol 2019; 37: 255-267
• 5 Saulite I, Hoetzenecker W, Weidinger S. et al. Sezary syndrome and atopic dermatitis:comparison of immunological aspects and targets. Biomed Res Int 2016; 2016: 9717530
• 6 Guttman-Yassky E, Bissonnette R, Ungar B. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol 2019; 143: 155-172
• 7 Akinlade B, Guttman-Yassky E, de Bruin-Weller M. et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181: 459-473
• 8 Tran J, Morris L, Vu A. et al. Development of Sézary syndrome following the administration of dupilumab. Dermatol Online J 2020; 26: 13030/qt1m67z8sb
• 9 Espinosa ML, Nguyen MT, Aguirre AS. et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol 2020; 83: 197-199
• 10 Arlt A, Bonin F, Rehberg T. et al. High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination. Mol Oncol 2020; 14: 571-589
• 11 Elston D. Letter from the editor. Dupilumab and cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2020; 83: 33-34
• 12 Chiba T, Nagai T, Osada SI. et al. Diagnosis of Mucosis fungoides following administration of Dupilumab for misdiagnosed atopic dermatitis. Acta Derm venerol 2019; 99: 818-819
• 13 Larocca C, Kupper T. Mycosis Fungoides and Sezary Syndrome: An Update. Hematol Oncol Clin North Am 2019; 33: 103-120
• 14 Hollins CL, Wirth P, Fulchiero Jr G. et al. Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma. Cutis 2020; 106: E8-E11